The utilization of drug-gene testing, also known as pharmacogenomics (PGx), has gained significant traction over the past year and will remain a revolutionizing tool that is shaping the future of precise medication prescribing. We can now confidently transform experimental PGx programs into comprehensive PGx hubs for larger patient communities. We will see amplification in the use of PGx test results by healthcare providers to elevate their therapeutic decisions and select effective interventions sooner.

PGx test insights enable ongoing care monitoring over time and care teams will build confidence in relying on them daily in their decision-making. An aging population is increasing the demand for healthcare. The transformative role of proactive PGx-informed medication management for complex and aging patients, along with other clinical and lifestyle variables, will be evident in specialized and primary care settings.


Organizations will be transitioning their siloed and often nascent PGx initiatives toward a model that leverages cohesive delivery platforms. They will equip their care teams with scalable and operationally efficient genomics solutions, allowing healthcare providers to focus on delivering quality care. Efficient solutions will be needed to help care providers address clinical relevance, workflow, and operational challenges while reducing cognitive burdens.

As we gain further real-world evidence on the performance of PGx programs, especially in chronic disease management, organizations will establish PGx testing as a cost-effective standard of care. There will be an increase in the use of real-world evidence to explore AI’s potential in accelerating the discovery of novel drug targets and facilitating the repurposing of treatment modalities for chronic and costly disorders. The ability of AI to make sense of large amounts of patient records is well-positioned to help organizations screen patient cohorts and unlock opportunities to improve care with genomic insights.

- Houda Hachad, PharmD, M. Res, Vice President of Clinical Operations, Aranscia

Business Affairs Homepage